NCT00520104

Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine

A Randomized, Open Label, Single Center, Single-Dose Study to Assess the Effects of Certain Nasal Medications on the Pharmacokinetics, Safety and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Javelin Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.

Detailed description

To assess separately the effects of a nasal vasoconstrictor (oxymetazoline) and of a nasal steroid on the rate and extent of intranasal absorption of PMI-150 30 mg.

Conditions

• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	intranasal ketamine	drug interaction

Timeline

• Start date: 2007-08-01
• Primary completion: 2008-02-01
• Completion: 2008-03-01
• First posted: 2007-08-23
• Last updated: 2008-02-29

Locations

1 site across 1 country: United States